Peptide Comparison
Pentapeptide-18 vs Syn-Ake
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Pentapeptide-18 and Syn-Ake share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: minimal. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Pentapeptide-18 | Syn-Ake | |
|---|---|---|
| Class | Cosmetic peptide; enkephalin mimetic | Cosmetic peptide (snake-venom inspired) |
| Drug class | Dermatologic | Dermatologic |
| Mechanism | Enkephalin mimetic; modulates SNAP-25 at muscle-neuron interface (topical) | Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle |
| Route | Topical | Topical |
| Half-life | Topical | Topical |
| Dosage (research) | Topical 2-10% | Topical 4% |
| Evidence tier | Cosmetic Clinical Studies | Cosmetic Clinical Studies |
| Research depth | 11 indexed | 5 indexed |
| Availability | Cosmetic | Cosmetic |
| Reported risks | Minimal | Minimal |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Pentapeptide-18 or Syn-Ake?
Pentapeptide-18 and Syn-Ake share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between Pentapeptide-18 and Syn-Ake?
Pentapeptide-18 is classed as Cosmetic peptide; enkephalin mimetic; Syn-Ake is classed as Cosmetic peptide (snake-venom inspired). Reported mechanism: Pentapeptide-18, Enkephalin mimetic; modulates SNAP-25 at muscle-neuron interface (topical); Syn-Ake, Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle. Reported half-life: Pentapeptide-18, Topical; Syn-Ake, Topical. Routes in published studies: Pentapeptide-18, Topical; Syn-Ake, Topical.
Which has stronger evidence, Pentapeptide-18 or Syn-Ake?
Pentapeptide-18 and Syn-Ake sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Pentapeptide-18 is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 11 indexed studies. Syn-Ake is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 5 indexed studies.
Which is more accessible, Pentapeptide-18 or Syn-Ake?
Neither Pentapeptide-18 nor Syn-Ake is an FDA-approved drug. Catalog status: Pentapeptide-18, Cosmetic; Syn-Ake, Cosmetic.
Are Pentapeptide-18 and Syn-Ake ever combined?
Pentapeptide-18 and Syn-Ake appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…